Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity and Safety Study of FluarixTM Vaccine in Children Who Have Previously Been Vaccinated With PandemrixTM

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects having previously been immunized with only one single dose of Pandemrix at the age of 10-17 years inclusive.~* Subjects having received Pandemrix at least six months prior to study enrolment.~* Subjects who the investigator believes that subject and/or parent(s)/Legally Acceptable Representative(s) \[LAR(s)\] can and will comply with the requirements of the protocol~* Written informed consent obtained from the subject/ the parent(s)/LAR(s) of the subject.~* Healthy subjects as established by medical history and clinical examination before entering into the study.~* Subjects or Parent(s)/LAR(s) with access to a consistent means of telephone contact, land line or mobile, but NOT a pay phone or other multiple-user device~Exclusion Criteria:~* Active participation in other clinical trials.~* Use of any investigational or non-registered product other than the study vaccine within 30 days preceding the first dose of the study vaccine or planned use during the study period.~* Planned administration of any vaccine 30 days prior and 30 days after any study vaccine administration.~* Chronic administration of immunosuppressants or other immune-modifying drugs within three months prior to enrolment in this study or planned administration during the study period.~* Acute disease and/or fever at the time of enrolment:~* Acute or chronic, clinically-significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by medical history and physical examination.~* Administration of immunoglobulins and/or any blood products within the three months prior to the enrolment in this study, or planned use during the study.~* Any confirmed or suspected immunosuppressive or immunodeficient condition based on medical history and physical examination~* Any known or suspected allergy to any constituent of influenza vaccines; a history of anaphylactic-type reaction to any constituent of influenza vaccines; or a history of severe adverse reaction to a previous influenza vaccine.~* History of seizures or progressive neurological disease.~* Subjects having received an H1N1v pandemic vaccine other than Pandemrix or having received the 2010/2011 seasonal influenza vaccine.~* If the subject is female and if she is of childbearing potential, she must practice adequate contraception for 30 days prior to vaccination, have a negative pregnancy test and continue such precautions for two months after completion of the vaccination series.~* Child in care.

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: 18 Years
- Healthy Volunteers: t

Study Arms:
- Fluarix Group (Type: EXPERIMENTAL): Subjects previously vaccinated with Pandemrix vaccine received 1 dose of Fluarix vaccine. All vaccines were administered in the deltoid region of the non-dominant arm on Day 0.
- Havrix Group (Type: ACTIVE_COMPARATOR): Subjects previously vaccinated with Pandemrix vaccine received 1 first dose of Havrix vaccine (subjects aged above 15 years) or Havrix-Junior vaccine (subjects aged 15 years and below). A second dose was given outside the study setting, at Month 6. All vaccines were administered in the deltoid region of the non-dominant arm on Day 0.

Based on this trial design, predict the completion outcome and termination type (if applicable).